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Available online 3 March 2015Background: Transrectal ultrasound-guided prostate biopsies are prone to detection errors. Multi-
parametric MRI (MP-MRI) may improve the diagnostic pathway.
Methods: PROMIS is a prospective validating paired-cohort study that meets criteria for level 1
evidence in diagnostic test evaluation. PROMIS will investigate whether multi-parametric (MP)-
MRI can discriminate between men with and without clinically-significant prostate cancer who
are at risk prior to first biopsy. Up to 714menwill haveMP-MRI (index), 10–12 core TRUS-biopsy
(standard) and 5 mm transperineal template mapping (TPM) biopsies (reference). The conduct
and reporting of each test will be blinded to the others.
Results: PROMIS will measure and compare sensitivity, specificity, and positive and negative
predictive values of bothMP-MRI and TRUS-biopsy against TPM biopsies. TheMP-MRI results will
be used to determine the proportion ofmenwho could safely avoid biopsywithout compromising
detection of clinically-significant cancers. For the primary outcome, significant cancer on TPM is
defined as Gleason grade N/= 4 + 3 and/or maximum cancer core length of ≥6 mm. PROMIS
will also assess inter-observer variability among radiologists among other secondary outcomes.
Cost-effectiveness of MP-MRI prior to biopsy will also be evaluated.
Conclusions: PROMIS will determine whether MP-MRI of the prostate prior to first biopsy
improves the detection accuracy of clinically-significant cancer.
© 2015 TheAuthors. Publishedby Elsevier Inc. This is an openaccess article under the CC BY license
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nc. This is an open access articl1. Background & introduction
Prostate cancer is the most common male cancer, with a
doubling in incidence over the last 15 years in the UK.
Currently over 40,000 new cases are diagnosed every year in the
UK [1,2] and 223,307 new cases in the USA [3]. Many prostate
cancers currently detected are clinically insignificant and do not
have any clinical impact on the individual during his remaining
life if left untreated [4,5]. This assertion has received consider-
able support from a number of large randomised controllede under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Over-detection of insignificant prostate cancer resulting from TRUS-
guided biopsies.
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PLCO (Prostate, Lung, Colon and Ovaries) screening trial in the
USA showed no evidence of a survival benefit it was criticised
for significant contamination (i.e., PSA testing) in the control
arm [6]. The European Randomized Study of Screening for
Prostate Cancer (ERSPC) showed a modest reduction in risk of
death from prostate cancer in those screened [7]. The number
needed to invite for screening was 936 and the number of
prostate cancers needed to detect and/or treat was 33 to extend
the life of one man over a 12 year period [8–10]. Further, the
benefit of PSA screening was diminished by loss of quality-
adjusted life-years owing to post-diagnosis long-term effects
[10].
The role of treatment, once diagnosed, has also been
questioned. The Scandinavian Prostate Cancer Group-4 (SPCG-
4) and the Prostate Cancer Intervention Versus Observation
Trial (PIVOT) randomised controlled trials of radical prostatec-
tomy compared to watchful waiting have shown that the
benefit of treatment in terms of improved overall survival was
restricted to thosemenwith higher risk – clinically significant –
prostate cancer [11–14].
In order to minimise over-diagnosis and over-treatment,
the optimal diagnostic pathway should be able to discriminate
reliably between men with and without clinically significant
cancer.
2. The current diagnostic pathway
Men deemed at risk of prostate cancer are those with an
elevated PSA level, an abnormal digital rectal examination, a
positive family history of prostate cancer or a specific ethnic
profile [15]. Once a risk factor is identified, patients are
advised to have a trans-rectal ultrasound (TRUS) guided
biopsy. Annually, between 59,000 and 80,000 men have a
TRUS-biopsy in the UK and about one million in the USA [16].
TRUS-biopsy can be problematic in that the ultrasound is
used to identify the prostate itself and is unable to identify
suspicious lesions with any degree of accuracy; this results in
biopsies being taken blindly throughout the prostate. This is in
contrast to the approach taken in most other solid organ
cancers where the lesion is identified, usually on imaging, in
order to direct biopsies to the area of suspicion. The random
and systematic errors in diagnosis which are inherent in TRUS-
biopsies lead to a number of problems.
2.1. TRUS biopsies over-diagnose clinically insigniﬁcant prostate
cancer
A man who undergoes TRUS-biopsy has a 1 in 4 chance of
being diagnosed with prostate cancer [17,18]. This compares
with a 6–8% lifetime risk of having prostate cancer that will
impact life expectancy. The over-detection of these small low-
grade lesions is due in part to the random deployment of the
needles [17–19] (Fig. 1).
2.2. TRUS-guided biopsies miss clinically signiﬁcant cancers
They have an estimated false negative rate of 30%–45%
[19,20]. The clinician takes 10–12 biopsies in a manner that
attempts to obtain representative tissue from the peripheral
zone (Fig. 2a). However, this systematic error leads to significantcancer being missed in the peripheral zone. Further, several
parts of the prostate are systematically under-sampled. First, the
anterior gland is missed as a result of its greater distance from
the rectum (Fig. 2b). Second, areas in the midline are under-
sampled due to efforts to avoid the urethra. Third, the prostate
apex is often difficult to access by the transrectal route [21–24].
2.3. TRUS-biopsies can misrepresent the true burden of cancer
The random sampling error (Fig. 2c) canmean that a biopsy
does not hit the cancer lesion through its greatest diameter
leading to either or both the size or grade of cancer being
underestimated [25] (Fig. 2c). Up to half of men deemed low
risk on TRUS-biopsies can have higher burden or grade, or both,
when a more accurate biopsy test is applied [22–24,26–28]. As
a result of the poor risk attribution, many men with true low
risk disease cannot be sure of their risk attribution so they and
their physicians often choose radical therapies fromwhich they
derive little to no survival benefit [11].
2.4. TRUS-biopsy has harms
It is associated with a number of complications, the most
important being urinary tract infection (1–8%) that can
result in life-threatening sepsis (1–4%). Haematuria (50%),
haematospermia (30%), pain/discomfort (most), dysuria
(most) and urinary retention (1%) can also be expected
[29–32].
3. The proposed new diagnostic pathway
Anovel pathway (Fig. 3) inwhich imaging is used as a triage
test [33] for men at risk of prostate cancer might enable
physicians to decide if the patient should or should not have a
prostate biopsy,whilst those patientswith a visible lesion could
have a targeted biopsy.
This proposed newpathwaymight offer several advantages.
Should the results of the trial be in favour of MP-MRI, we
hypothesise three corrections in the current pathway that
might occur. First, over-diagnosis might be reduced because
fewer clinically insignificant prostate cancers will be detected
by chance as only patients with positive MRIs will undergo a
biopsy. Second, as a result there might be less over-treatment.
Fig. 2. Under-detection of clinically significant prostate cancer resulting from TRUS-guided biopsies.
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might be improved. Fourth, there might be better treatment
allocation to active surveillance or radical therapies due to
more representative biopsy sampling and better risk stratifica-
tion. Fifth, complications might be reduced if fewer men are
biopsied [34,35].
At presentmulti-parametric MRI (MP-MRI) appears to have
the desired attributes of a test that could be used in the prostate
cancer diagnostic pathway [36]. The evidence base available at
the time of conceiving PROMIS suggested that MP-MRI can
achieve both a sensitivity and specificity between 70–90% for
the detection of clinically significant prostate cancer [37].
However, a systematic review of the literature [38] found the
quality of the initial studies evaluating MP-MRI to be disap-
pointing [36]. Early reports repeatedly showed low sensitivity
and specificity as well as high inter-observer variability, even
when using high-resolution endorectal MRI [39–45]. Since
these early reports, much has changed including an apprecia-
tion of the impact of post-biopsy changes onMR-image quality,
technological improvements such as increasing magnetic
field strength (from 0.5 T to 1.5 T and 3.0 T), shorter pulse
sequences enabling faster image acquisition, and the introduc-
tion of functional imaging in the form of diffusion weighting
(DW) and dynamic contrast-enhancement (DCE).
Multi-parametric approaches in which sequences are com-
bined together have found an advantage for using two or three
MRI sequences rather than just one. When PROMIS started,
none had evaluated the clinical validity of MP-MRI in the
population of interest – men at risk – against an accurate and
appropriate reference standard within a prospective multi-
centre study (Table 1) [46–56].
There were a number of limitations to the early studies
investigating the diagnostic accuracy of MRI for prostate cancerthat probably account for the limited acceptance of MRI into
the prostate cancer diagnostic pathway [57]. These include:
a) biopsy artefact: studies mostly evaluate MRI after biopsy.
This results in biopsy-related haemorrhage and inflamma-
tion, which can lead to false positives or negative results or
scans which are not interpretable.
b) Limited application: many studies evaluated only the periph-
eral zone of the prostate, ignoring up to one-third of prostate
cancers that lie anteriorly.
c) Segmentation: most studies segmented the prostate into a
number of sectors for analysis in order to both achieve
sufficient matched datasets. These studies classify each
sector of analysis as ‘independent’. Segmentation is usually
employed because the reference used is radical whole-
mount prostatectomy.
d) Inaccurate or inappropriate reference standard: most studies
used radical prostatectomy (RP), leading to selection bias as
men have to test positive on a biopsy first and then choose
to have surgery. Those undergoing surgery tend to have
burdens of cancer that are distinct from patients choosing
other treatments [58]. Further, as the prostate is usually
segmented, co-registration of an image to an RP specimen
is challenging because of shrinkage (10–20%), distortion,
tissue loss as a result of ‘trimming’ (10%), orientation,
absent perfusion and sector boundaries [59,60].
4. Design and methods: the PROMIS protocol
4.1. Design
PROMIS is a validating paired cohort study representing level
1 evidence for diagnostic studies [61]. The primary objectives of
Fig. 3. Current and proposed diagnostic pathways should MP-MRI prove favourable.
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can safely avoid unnecessary biopsy and to assess the ability of
the MP-MRI based pathway to improve the rate of detection of
clinically significant cancer by evaluating the diagnostic accuracy
of MP-MRI (the index test) against an accurate reference
standard, template prostate mapping (TPM) biopsies, which
can be applied to all men under evaluation. The current TRUS-
biopsy (standard test) will also be evaluated against TPM. All
men consenting to the study will have a MP-MRI, followed by a
combined prostate biopsy procedure in which TPM biopsies
will be followed by TRUS-guided biopsies. Each test will be
conducted and reported independent of the other tests (Fig. 4).
PROMIS is designed to overcome shortcomings highlighted
in the current literature. First, since all patients will be biopsy-Table 1
Sensitivity and speciﬁcity of MRI parameters as reported in the literature.
Parameter Number (mean) Sensitivity Speciﬁcity
T2 12–320 (97) 37–96% 21–67%
DW 11–95 (42) 57–90% 79–88%
DCE 23–54 (41) 71–87% 61–89%naïve and undergo MP-MRI prior to any biopsy, there will be
no biopsy artefact. Second, MP-MRI will be evaluated for all
anatomical zones of the prostate including peripheral and
transition zones. Third, the study is powered so that the
primary outcome will be derived using the whole prostate as
the sector of analysis rather than segmented sectors of the
prostate. Fourth, PROMIS employs an accurate reference test
that can be applied to all men at risk.
Furthermore, the study has been designed to ensure
avoidance or minimisation of a number of biases that are
inherent in the current literature. First, spectrum and selection
biases will be avoided by recruiting men at risk of prostate
cancer and applying all tests to all men. Second, work-up bias
will be eliminated by ensuring that patients and clinicians
remain blinded to all imaging test results until the biopsies
have been carried out and reported. Third, reviewer/reporter
bias will be avoided by ensuring that the radiologist is blinded
to the reference test and the pathologist is blinded to the
imaging. The radiology report in particular will be submitted
prior to the biopsies. Last, incorporation bias is minimised by
ensuring that TPM biopsies and TRUS-guided biopsies follow a
standard accepted protocol.
N.B: visit one (registration) includes a detailed discussion of the patient  
information sheet and what to expect from participation in PROMIS. Followed by 
signing an informed consent and assessment of patient’s eligibility.
Fig. 4. PROMIS Trial Schema. N.B.: visit one (registration) includes a detailed discussion of the patient information sheet and what to expect from participation in
PROMIS. Followed by signing an informed consent and assessment of patient's eligibility.
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Men who have never had a prostate biopsy before are
eligible for the study if there is a clinical suspicion that they
may be harbouring prostate cancer. This essentially includes
men with an elevated PSA and/or a suspicious digital rectal
examination, family history of prostate cancer or an ethnic risk
group. Men with a PSA above 15 ng/ml are excluded from
PROMIS as physicians are unlikely to use MP-MRI as a triage
test to avoid a biopsy due to the higher incidence of prostate
cancer in this sub-group. The inclusion and exclusion criteria
are described in Table 2. Patientswho do notwant to participate
in PROMIS or who are ineligible are returned to the normal
clinical pathway employed in the participating centre.
4.3. Study interventions
4.3.1. The index test — multi-parametric magnetic resonance
imaging
Although experts in the field generally regard the perfor-
mance characteristics of MP-MRI of the prostate as promising[62], there exists professional disagreement on its accuracy
and usefulness in clinical practice [35], limiting wider
adoption. These concerns relate in part to the variable quality
and methodology of studies that have resulted in marked
variation in indication, conduct, interpretation, and reporting
[46,54,60,63–66].
As a result, MP-MRI in PROMIS will be standardised to
the minimal requirements advised by a European consensus
meeting [67], the European Society of Uro-Radiology [68] and
the British Society of Uro-Radiology guidelines [69]; this will
entail acquiring T1-weighted, T2-weighted, diffusion-weighted
(apparent diffusion coefficient maps and long-b scan) and
dynamic gadolinium contrast-enhanced imaging using a
1.5 Tesla scanner and a pelvic phased array (Table 3).
Use of endorectal coils will be avoided, as there is no
consensus on its role in minimal scanning requirements [67]. It
was decided to not include magnetic resonance spectroscopy
as evidence from a large prospective multicentre study at
the time showed no benefit of spectroscopy for prostate
cancer localization compared with T2-weighted imaging
alone [70].
Table 2
Patient inclusion and exclusion criteria.
Patient inclusion criteria
Men at least 18 years or over at risk of prostate cancer who have been
advised to have a prostate biopsy
Serum PSA ≤ 15 ng/ml within the previous 3 months
Suspected stage ≤ T2 on rectal examination (organ conﬁned)
Fit for general/spinal anaesthesia
Fit to undergo all protocol procedures including a transrectal ultrasound
Signed informed consent
Patient exclusion criteria
Treated using 5-alpha-reductase inhibitors at time of registration or
during the prior 6 months
Previous history of prostate biopsy, prostate surgery or treatment for
prostate cancer (interventions for benign prostatic hyperplasia/
bladder outﬂow obstruction is acceptable)
Evidence of a urinary tract infection or history of acute prostatitis within
the last 3 months
Contraindication to MRI (e.g., claustrophobia, pacemaker, estimated
GFR ≤ 50)
Any other medical condition precluding procedures described in the
protocol
Previous history of hip replacement surgery, metallic hip replacement or
extensive pelvic orthopaedic metal work.
31A. El-Shater Bosaily et al. / Contemporary Clinical Trials 42 (2015) 26–40In order to maintain the quality of scans and ensure
uniformity across all centres, optimization of the conduct of
scans will be applied to all centres through a robust quality
control process. This will be undertaken by a separate
independent commercial sub-contractor (Ixico Ltd, UK) select-
ed through an open competition compliant with the European
Union guidelines on the tender process. Scans deemed of
insufficient quality by the commercial partner or the reporting
radiologist will be repeated.
4.3.1.1. Standardization of MRI reporting. In order to avoid
variation in method of interpretation, a standardised operating
procedure for MP-MRI reporting has been adopted in line with
the recommendations of the European consensus meeting and
the European Society of Uro-Radiology prostate MRI guidelines
[68]. All radiologists will undergo training and standardisation
of reporting by the lead radiologist centrally prior to reporting
within the trial. The actual reportingwill require all radiologists
being provided with the same clinical details including PSA,
DRE findings and any other risk factors. Imageswill be reported
in sequence so that T2-weighted images will be reported first,
T2-weighted and diffusion-weighted together and then a third
report issued for T2-weighted with diffusion and dynamicTable 3
Standard operating procedure for MRI parameters for all centres to follow.
TR TE Flip angle/
degrees
Plane
T2 TSE 5170 92 180 Axial, coronal,
sagittal
VIBE at multiple ﬂip angles for
T1 calculation (optional)
VIBE fat sat 5.61 2.52 15 Axial
Diffusion (b values: 0, 150,
500, 1000)
2200 Min (b98) Axial
Diffusion (b = 1400) 2200 Min (b98) Axialcontrast enhanced scans together. A separate report will be
produced for each combination of sequences in order to
secondarily investigate whether both diffusion-weighted and
DCE are both required. As DCE requires contrast agent (with its
need for intravenous access, medical supervision and contrast-
related risks) and an additional 10–15min of scan time there is
considerable merit in determining whether this additional
resource and cost is necessary (Fig. 5).
A 1 to 5 Likert scoring system [67,68,71] will be used to
indicate probability of cancer (1 — highly likely to be benign,
2— likely to be benign, 3— equivocal, 4— likely to bemalignant
and 5— highly likely to bemalignant)with the prostate divided
into 12 regions of interest (ROI) and each region scored from 1
to 5. Further, each lesion will be identified and scored on the 1
to 5 scale separately and the longest axial diameter, lesion
volume, ADC value and contrast enhancement curve type will
be recorded [72–75]. An overall 1 to 5 score of the whole
prostate will be recorded for each level of cancer burden
that the radiologist thinks might be present. This will be ‘all
cancer’, ‘definition 1 clinically significant cancer’ and ‘definition
2 clinically significant cancer’ (see below).
With respect to the primary outcome, an overall score of
3 or more will be used to indicate the possible presence of
clinically significant cancer (i.e., a positive MP-MRI score). This
reflects the level at which further tests (e.g., biopsy) would be
considered ifMP-MRIwere to be introduced into the diagnostic
pathway in the future.
4.3.1.2. Assessing for inter-observer variability and quality control
and assessment. In order to establish if a diagnostic test can
improve or change the diagnostic pathway in prostate cancer, it
must be assessed for intra- and inter-observer variability. Thus, a
subset of scans will be reported by another experienced central
radiologist. A subset of scans will also be reported by the same
reporter again at a different time-point to assess intra-observer
variability.
In order tomake sure that the result of theMP-MRI does not
influence the conduct of the biopsy, the results of the MP-MRI
will not be revealed to either the men having the biopsies or
to the clinicians undertaking the biopsies until after the results
of the TRUS-biopsy and TPM biopsies are available (with the
exceptions for un-blinding given below). This blinding is
necessary to prevent the results of the MP-MRI influencing
whether men are biopsied and if they are, how the biopsies are
conducted.
For safety purposes, the results of the MP-MRI can be un-
blinded by the radiologist if the MP-MRI reveals an enlargedSlice thickness
(gap)
Matrix size Field of
view/mm
Time for scan
3 mm (10% gap) 256 × 256 180 × 180 3 min 54 s (ax)
Will be included in the
Phoenix ﬁle
3 mm 192 × 192 260 × 260 Continue for at least 5 min
30 s after contrast
5 mm 172 × 172 260 × 260 5 min 44 s (16 averages)
5 mm 172 × 172 320 × 320 3 min 39 s (32 averages)
Fig. 5.MP-MRI reporting form.
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cancer or involved lymph nodes or colorectal/bladder invasion.
The presence of other cancers such as bladder or colorectal
cancers will also be a criterion for withdrawal. This information
will be provided to the treating clinician for appropriate clinical
decision making.
4.3.2. The standard test — transrectal ultrasound-guided biopsy
TRUS-biopsy of the prostate is to be performed after TPM
biopsies, under the same general/spinal anaesthetic. This helps
ensure that results are obtained for the reference test in an
optimal fashion in a biopsy naïve gland that has not undergone
swelling and distortion. It also theoretically minimises the
risk of infection as the potential for faecal contamination is
restricted to the end of the procedure. The surgeon performing
the biopsy procedure will be blind to the MRI results so no
targeting of suspicious areas will occur. TRUS-guided biopsies
incorporate 10–12 core biopsies taken as per international
guidelines [76]. Each core will be identified and potted
separately. The TPM biopsies and TRUS-guided biopsy sets
from a particular patient will be sent to different patholo-
gists to minimise review and work-up biases.
4.3.3. Comparator
4.3.3.1. Transperineal Template Prostate Mapping biopsies.
Transperineal Template Prostate Mapping (TPM) biopsies
(Fig. 6) has been selected as the reference test; when using
5mm-sampling itmeets the required specification as a reference
test for our defined population [24,26,77–80].
TPM biopsies produce a histological map of the entire
prostate in 3-dimensions with an estimated sensitivity and
negative predictive value (NPV) in the order of 95% for
clinically significant cancers when assessed against radical
prostatectomy [21,24]. TPM biopsies have a similar side-effect
profile to that of TRUS-biopsy with three important differences.
First, they carry a significantly lower risk of urosepsis (b0.5%) –
the most serious complication of TRUS-biopsy – as the needles
do not traverse the rectal mucosa. Second, TPM biopsies confer
a higher risk of self-limiting failure to void urine (5–10%) as aFig. 6. Illustration of how Transperineal Templateresult of greater gland swelling [78,81,82] compared to 1–2%
risk associated with TRUS-biopsy. Third, TPM biopsies require a
general/spinal anaesthetic. The accuracy of TPMbiopsies is high
and has been recently validated against radical whole-mount
specimens [83]. We chose to combine TPM biopsies with TRUS-
biopsies under the same general/spinal anaesthetic in order to
reduce patient burden (from two visits and two procedures to
one visit) and minimise drop-out of patients between tests.
Trainingwill be provided to all centres to conduct TPM biopsies
according to the PROMIS protocol although all centres have
been selected for their prior experience in carrying out TPM
biopsies.
4.3.3.2. Side effect proﬁle of a combined TPM and TRUS-biopsy
procedure. The expected side-effects of combining both proce-
dures is detailed in the patient information sheet which is
discussed with all patients prior to registration (Table 4). Our
rate of serious adverse events is monitored by an independent
trial steering committee on a weekly basis.
4.4. The target condition for detection — deﬁning clinically
signiﬁcant prostate cancer
Despite the high accuracy of TPM biopsies in detecting
clinically significant disease there is no widespread agreement
on the criteria to define clinically significant prostate cancer on
TRUS-biopsies or TPM biopsies. Whilst some definitions exist,
such as the Epstein criteria [84], they have been developed for
TRUS-biopsy; indeed, if these were applied to TPM biopsies the
prevalence of intermediate and high risk disease would be
artificially inflated given the different sampling densities used
[28,85]. As a consequence, the best evidence to select the risk
classification for analysing TPM biopsy results has been derived
by a simulation studyusing TPM-biopsieswith a 5mmsampling
density. By combining maximum cancer core length and
Gleason score, this simulation study stratified patients into
three groups: low risk, intermediate risk and high risk (Fig. 7).
The target definition for clinically significant disease on TPM
biopsies for the primary outcome will be set at a maximum
cancer core involvement N/=6 mm and/or Gleason N/=4 + 3Prostate Mapping biopsies are conducted.
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an area of cancer on TPM biopsies that approximates to a lesion
volume of N/=0.5 ml [17]. We chose this target condition as
the primary outcome on the basis that few physicians
would disagree that any man having this burden of cancer
would require treatment. A further threshold for clinically
significant disease will also be used (cancer core length
involvement N/=4 mm and/or Gleason N/=3 + 4) (UCL
definition 2).
4.5. Outcomes
4.5.1. Primary outcomes
The primary outcomes in this trial are of fundamental
importance to decisions regarding the future use of MP-MRI in
the diagnostic pathway for the prostate cancer. First, they
include the proportion of men who could safely avoid biopsy
as determined by specificity and negative predictive values
(NPVs) for clinically significant cancer. Second, the proportion
of men correctly identified by MP-MRI to have clinically
significant prostate cancer as determined by sensitivity and
positive predictive values (PPV). For the primary outcomes,
UCL definition one criteria will be used to set the target
definition of clinically significant prostate cancer on TPM
biopsy and a score of 3 or more on MP-MRI will be used to
define a positive index test. Further, the accuracy of TRUS-
biopsy will also be reported in terms of sensitivity, specificity,
NPV, and PPV as listed in the section below. In addition, a head-
to-head comparison of the accuracy of MP-MRI versus TRUS-
guided biopsy (current standard)will be performed. All primary
and secondary outcomes are presented in Table 5.
4.6. Translational objectives
PROMIS is ideal for assessing the utility of biomarkers (from
urine and blood) to identify men with clinically significant
prostate cancer. This is the first time that a broad spectrum of
men at riskwill be evaluated using anoptimal biopsy technique
that accurately characterises the presence, size and grade of
prostate cancer. We will collect, process and store a compre-
hensive bank of tissue samples (serum, plasma, germ-lineDNA,
urine) from men prior to biopsy, to analyse urinary and serum
biomarkerswith respect to the detection of clinically significant
prostate cancer on TPM biopsy.
4.7. Trial conduct
The study has been set up to run in two stages: the pilot
phase, followed by the main phase. The pilot study has already
completed and recruited 50 patients over one year to allow
testing of safety and recruitment. At the end of the pilot in May
2013, few safety concerns emerged and the Trial Steering
Committee recommended continuation of the study into the
main phase [86].
If the combination of TRUS-biopsy and TPM biopsies leads
to more than a 4% risk of sepsis at any time, there could be
cause for concern and a requirement for modification of
the study design. If deemed appropriate, recruitment to the
study will be suspended until any safety concerns have been
resolved.4.8. Long-term follow-up through linkage
The long-term outcomes of the PROMIS cohort will be of
interest and contribute to our understanding of the epidemi-
ology of prostate cancer. Menwho specifically consent to long-
term data collection will be flagged and followed up using the
Office for National Statistics and NHS databases. For example,
linkage to Hospital Episode Statistics (HES) may give valuable
information on further diagnoses, treatments and outcomes
beyond the timeframe of the study for future analyses.
Consenting men may additionally be contacted in the future to
assess their willingness to respond to questionnaires. This
allows the potential for research that would complement the
planned long-term follow-up in terms of health status, for
example picking up future biopsies not included in HES, and
allows assessment of quality of life.4.9. Statistical considerations
4.9.1. Sample size
Power calculations were performed in relation to: (1) preci-
sion around the estimates for the accuracy of MP-MRI in terms
of the joint primary outcomes of specificity and sensitivity, and
(2) a head-to-head comparison of the MP-MRI versus TRUS.
The largest sample size from (1) and (2) was 714 (as detailed
below) and this was taken as the maximum number of men
required to have all 3 tests (MP-MRI, TRUS biopsy and TTPM-
biopsies).4.9.2. Prevalence of clinically signiﬁcant cancer
For all calculations we have assumed [19,20,28,87] that 15%
of the study population will have clinically significant prostate
cancer as detected by the reference standard according to UCL
definition one and 25% will have clinically significant prostate
cancer as detected by the reference standard according to UCL
definition two. These estimates act as inflation factors for
the total number of men required for the study. All calculations
are based on 90% power and 5% significance (2-sided). The
specified estimates of sensitivity and specificity are considered
realistic based on current unpublished and published literature
[88,89] (Fig. 8).4.9.3. Speciﬁcity of MP-MRI
Assuming a specificity of 77%, in order to demonstrate that
the lower 95% confidence interval of specificity is at least 70% or
greater, we would require 407 cases of negative or clinically
insignificant prostate cancer. This is equivalent to a total of 479
men for UCL definition one and 543men for UCL definition two.4.9.4. Sensitivity of MP-MRI
Assuming a sensitivity of 75%, in order to demonstrate that
the lower 95% confidence interval of sensitivity is at least 60%
or greater, we would require 97 cases of clinically significant
prostate cancer. This is equivalent to a total of 647men for UCL
definition one and 388 men for UCL definition two. Since the
number of men without clinically significant prostate cancer
will be much higher than the number with, the precision for
estimating specificity and NPV is much greater.
Table 4
Combined prostate biopsy procedure side effect proﬁle as stated in the patient information sheet and consent documentation.
Side effect Procedure
TRUS alone (standard care) Combined biopsy: TPM + TRUS (in the PROMIS study)
Pain/discomfort Almost all men experience temporary discomfort
in the rectum
Almost all men experience temporary discomfort in
the rectum
Burning when passing urine Almost all men Almost all men
Bloody urine 1 in 2 men (self-resolving, 2–3 days) Almost all men (self-resolving, 2–3 days)
Bloody sperm 3 in 10 men (2–3 months to resolve) Almost all men (lasting up to 3 months)
Poor erections 3 in 10 men (self-resolving after 6–8 weeks). Rarely,
tablets may be needed to help the erections improve.
Almost all men (self-resolving after 6–8 weeks). Rarely,
tablets may be needed to help the erections improve.
Infection of skin or urine 1–8 in 100 men 1–8 in 100 men
Infection of skin or urine requiring admission
and intravenous antibiotics
Between 1–4 in 100 men Between 1–4 in 100 men
Difﬁculty passing urine 1 in 100 men 1–3 in 20 men
Bruising of skin None Almost all men
Bruising spread to scrotum None Between 1 in 20 to 1 in 10 men
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Wehave assumed that TRUS-biopsy detects 48% of clinically
significant prostate cancer [28,90] and MP-MRI will detect at
least 70% (conservative estimates). Using McNemar's test for
paired binary observations [91], in order to show an absolute
increase in the proportion of clinically significant cancers
detected of at least 22% (from 48% to 70%) with a power of
90% and a 2-sided alpha of 5%, a total of 107 cases are required.
This is equivalent to a total study population of 714 men for
UCL definition one and 428 men for UCL definition two.
4.9.6. Cost effectiveness analyses
A model will be populated from the study as well as a
review of secondary sources of epidemiological, clinical and
economic evidence together with appropriately elicited expert
opinion [92]. The use of probabilistic sensitivity analysis, value
of informationmethods and scenario analysis [93]will quantify
the uncertainty associated with identifying the most cost-
effective diagnostic strategy, the costs of that uncertainty (in
health and resource terms) and the key uncertainties to resolve
with further research. This will inform the inputs into themain
economic model. This cost-effectiveness model will seek to
quantify the long-term implication of changes to the diagnostic
classification of prostate cancer that result from adoption of
alternative diagnostic pathways within the NHS. The implica-
tions will relate to the health effects (in terms of qualityFig. 7. Definitions of clinical significance on TTPM-biopsy. Red signifies UCL definition
definition 2 and is a secondary outcome.
From Ahmed HU et al., J Urol, 2011; 186(2):458-64.adjusted life expectancy) and NHS costs of a given diagnostic
pathway placing patients into each of the four groups: 1. MRI
test positive, clinically significant disease; 2. MRI test negative,
clinically significant disease; 3. MRI test positive, clinically
insignificant disease; and 4. MRI test negative, clinically
insignificant disease. By altering the likelihood of a man falling
into any one of these groups, the value of MP-MRI will be
assessed by the changes in average outcomes experienced by
men and the costs that result. The model will also include the
implications of a positive result in the index test concurrent
with a negative result in the current standard as well as
accounting for the side effect profile of different diagnostic
pathways. Structurally, the model will consist of a diagnostic
element that will model the probabilities of a given patient
falling into each of the diagnostic groups above, and a
prognostic element that will estimate the long term implica-
tions for health and costs. The specific details of model
structure will be informed by a review of existing prostate
cancer models including those relating to screening, diagnosis
and treatment. In general terms the modelling will adhere to
the methods advocated to inform guidance by the UK National
Institute for Health and Clinical Excellence [94].
We will also collect data on the costs of tests and the
management of adverse events, and the health-related quality
of life (HRQL) implications of any adverse events experienced
with tests. The latter will be assessed using the EQ-5D1 against which the primary outcome will be validated. Yellow signifies UCL
Table 5
Primary and secondary outcomes for the PROMIS trial.
Primary outcomes:
Proportion of men who could safely avoid a biopsy as determined by
speciﬁcity and negative predictive values (NPV), based on deﬁnition
one of clinical signiﬁcance as assessed by TPM.
Proportion of men correctly identiﬁed by MP-MRI to have clinically
signiﬁcant prostate cancer as determined by sensitivity and positive
predictive value, based on deﬁnition one of clinical signiﬁcance as
assessed by TPM.
Secondary outcomes:
The proportion of men who could safely avoid biopsy, given that they do
not have deﬁnition two prostate cancer as assessed by TPM.
The proportion of men testing positive on MP-MRI out of those with
DEFINITION TWO prostate cancer assessed by TPM.
Performance characteristics of TRUS versus TPM (sensitivity, speciﬁcity,
NPV, PPV) according to deﬁnitions one and two
Evaluation of the optimal combination of MP-MRI functional parameters
(T2, DW, DCE) to detect or rule-out clinically signiﬁcant prostate
cancer.
Intra-observer variability in the reporting of MP-MRI.
Inter-observer variability in the reporting of MP-MRI.
Evaluation of socio-demographic, clinical, imaging and radiological
variables in relation to the detection of clinically signiﬁcant prostate
cancer.
Patients' health-related quality of life using the EQ-5D instrument.
Resource use and costs for further economic evaluation (see section on
Cost-effectiveness analyses).
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used generic measure of HRQL which can be used to derive
quality adjusted life years (QALYs) [95]. Ultimately, this work
will provide an assessment of the implications of any change
that the use of MP-MRI has on under-detection and over-
detection. These implications will be in terms of expected
quality adjusted survival duration and long-termhealth serviceFig. 8. Illustration summarizing some of the assumptions made in dcosts. This will allow the value for money of MP-MRI in this
context to be assessed using the same metrics employed to
evaluate therapeutic technologies by organisations such as
NICE.
4.10. Ethical considerations
The study abides by the principles of the Declaration of
Helsinki and the UK Research Governance Framework version
2 and received UK Research Ethics Committee approval on
16thMarch2011 by theNRES Committee London—Hampstead.
PROMIS is published on clinical trials.gov [96]
5. Discussion and limitations
The PROMIS protocol has some potential limitations. First,
the thresholds we have used for clinically significant disease are
open to debate as no universally accepted definition exists. It is
widely accepted that some prostate cancer lesions are clinically
significant and others are not [97,99]. Volume thresholds of
0.5 ml and 1.3 ml for low grade Gleason 6 lesions have been
supported by recent data from the European Prostate Cancer
Screening trial [98]. There are even some calls for such lesions to
be re-designated as something other than malignant, such is
their indolent behaviour [97,99,100]. However, we recognize
that there is legitimate professional disagreement on what
constitutes clinically significant prostate cancer, so we decided
to reflect this by using other disease burden thresholds to define
the target condition on the reference test for the purpose of
validating mpMRI.
Second, TPM biopsies may not be as accurate as whole-
mount prostatectomy, but a number of studies point to its
accuracy being sufficiently high to use as a reference test for the
specific population we will recruit. Indeed, for men with noetermining sample size calculations for the primary outcome.
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available reference standard.
Third, the sequence of TPM biopsy first followed by TRUS-
guided biopsy might compromise the standard test. However,
the decision for this sequence was one primarily based around
safety— inoculation of bacteria by TRUS-guided biopsy into the
gland followed by numerous TPM biopsies may theoretically
increase sepsis risk. We also wanted to ensure that the
reference test was not compromised by swelling caused by
the TRUS-guided biopsy if the latter was performed first.
Further, because TRUS-guided biopsies were being performed
under general/spinal anaesthetic with rectal cleansing per-
formed using 2% chlorhexidine solution might actually be
better than standard care in terms of sepsis and test accuracy.
6. Conclusion
PROMIS will determine whether introduction of MP-MRI
prior to biopsy can safely allow men to avoid a biopsy and its
associated harms. It will also determine whether MP-MRI
can better identify men with clinically significant disease that
requires a biopsy to confirm diagnosis using accurate targeting
to the lesion. The evidence produced by PROMIS will aid
current research interest investigating the possibility of
directing biopsies only to the suspicious areas on MRI
without deploying systemic biopsies.
Much research has focused on developing and validating
novel imaging and tissue biomarkers for early detection of
clinically significant prostate cancer. These programmes of
research have used TRUS-biopsy as the reference test with any
volume, grade and risk of cancer taken as a ‘positive’. PROMIS
aims to overcome the problems of TRUS-biopsy as a reference
test by using TPM biopsies that have a very high degree of
accuracy and can be applied to all eligible men. It therefore
represents an opportunity to develop and validate numerous
imaging and tissue biomarkers in their performance character-
istics to discriminate betweenmen at risk who have absence of
clinically significant cancer and those men who have clinically
significant cancer.
Trial status
Currently PROMIS is open for recruitment across 11 centres
in the United Kingdom with 3 more undergoing site setup
(Appendix 1). We are on target to conclude our recruitment.
Recruitment commenced inMay 2012 and is expected to come
to an end in October 2015.
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